Eli Lilly Balance Sheet Health
Financial Health criteria checks 3/6
Eli Lilly has a total shareholder equity of $14.3B and total debt of $31.2B, which brings its debt-to-equity ratio to 218.1%. Its total assets and total liabilities are $75.6B and $61.3B respectively. Eli Lilly's EBIT is $14.9B making its interest coverage ratio 28.7. It has cash and short-term investments of $3.5B.
Key information
218.1%
Debt to equity ratio
US$31.23b
Debt
| Interest coverage ratio | 28.7x |
| Cash | US$3.52b |
| Equity | US$14.32b |
| Total liabilities | US$61.29b |
| Total assets | US$75.61b |
Recent financial health updates
Recent updates
Eli Lilly: Still Much Room To Ride The Weight-Loss Wave
Jan 11Eli Lilly (NYSE:LLY) Will Pay A Larger Dividend Than Last Year At $1.50
Dec 28
Eli Lilly: A Rare Buying Opportunity
Dec 17Eli Lilly (NYSE:LLY) Has Announced That It Will Be Increasing Its Dividend To $1.50
Dec 14Lilly's Head-To-Head Data Lands Blow On Novo In Battle For Weight Loss Supremacy
Dec 04Here's Why Eli Lilly (NYSE:LLY) Can Manage Its Debt Responsibly
Nov 29Eli Lilly: An Early Christmas Present Has Just Arrived (Rating Upgrade)
Nov 28Eli Lilly Stock: Unexpected Developments (Rating Downgrade)
Nov 21Eli Lilly and Company Just Missed EPS By 31%: Here's What Analysts Think Will Happen Next
Nov 01Taking A Look At Eli Lilly's Q3 2024 Revenue Miss Amid Supply Chain Challenges
Oct 30Eli Lilly Buy On Weakness Signal (Technical Analysis)
Oct 20Eli Lilly: Ebglyss To Challenge Dupixent In Atopic Dermatitis
Sep 30Eli Lilly: I Admit Defeat As I Understated Its Growth Prospects (Upgrade)
Sep 20Eli Lilly (NYSE:LLY) Gains FDA Approval for EBGLYSS, Expands Strategic Alliances for Market Growth
Sep 18Eli Lilly: Zepbound Price Cuts Have Multiple Positives, Limited Downside
Sep 04Eli Lilly: Tirzepatide's Winning Streak Continues
Aug 20Financial Position Analysis
Short Term Liabilities: LLY's short term assets ($31.4B) exceed its short term liabilities ($24.7B).
Long Term Liabilities: LLY's short term assets ($31.4B) do not cover its long term liabilities ($36.6B).
Debt to Equity History and Analysis
Debt Level: LLY's net debt to equity ratio (193.5%) is considered high.
Reducing Debt: LLY's debt to equity ratio has reduced from 442.1% to 218.1% over the past 5 years.
Debt Coverage: LLY's debt is not well covered by operating cash flow (19.3%).
Interest Coverage: LLY's interest payments on its debt are well covered by EBIT (28.7x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/13 10:49 |
| End of Day Share Price | 2025/01/10 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Eli Lilly and Company is covered by 63 analysts. 29 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Ishan Majumdar | Baptista Research |
| Alistair Campbell | Berenberg |